Last updated: Aug 20, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07636785 | 1, 2 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors | Unknown mechanism |
| NCT07774247 | 2 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma | PD-L1 + VEGF + IL-6 receptor -- combination of immune checkpoint inhibition, anti-angiogenesis, and cytokine receptor blockade (monoclonal antibodies) |
| NCT06764316 | 1 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer | Unknown mechanism |
| NCT07291076 | 1, 2 | A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) | Unknown mechanism |
| NCT07722741 | 2 | Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC | Personalized neoantigens + IL-12 plasmid -- DNA vaccine and immunostimulatory cytokine gene therapy |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 38 |
| Tianjin Medical University Cancer Institute and Hospital | 17 |
| Second Affiliated Hospital of Guangzhou Medical University | 16 |
| Tongji Hospital | 15 |
| Fudan University | 14 |
Countries/regions with the most active trial sites for hepatocellular carcinoma. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Sep 30, 2026 | NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | VEGF -- monoclonal antibody (Bevacizumab); PD-1 -- immune checkpoint inhibitor (Sintilimab); Unknown target -- SYS6090 and SYS6043 mechanism unclear |
| Aug 2026 | NCT07430202 | A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | DNAJB1-PRKACA fusion kinase -- peptide vaccine plus glutamine antagonist plus PD-1 and CTLA-4 immune checkpoint inhibitors |
| Aug 2026 | NCT07705074 | FAPI PET Imaging - An Exploratory Study | Fibroblast activation protein (FAP) -- PET imaging tracer targeting FAP (radiotracer) |
| Jul 20, 2026 | NCT07714317 | Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet) | CTLA-4 + PD-1 + VEGF -- combination of immune checkpoint inhibitors and anti-angiogenic antibody |
| Jul 10, 2026 | NCT07627191 | GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | GLP-1 receptor -- receptor agonist (GLP-1 RA) |
| Jul 1, 2026 | NCT07365839 | Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma | PD-1 -- immune checkpoint inhibitor (cemiplimab) +/- CTLA-4 inhibitor (fianlimab) |
| Jul 2026 | NCT07709299 | Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection | Autologous immune cells -- cytokine-induced killer cell therapy |
| Jun 29, 2026 | NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | PD-1 + CTLA-4 + nucleoside analog -- immune checkpoint inhibitor plus nucleoside analog |
You've seen the hepatocellular carcinoma landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.